Latest News

The spending fueling the boom hasn't let up, so should investors be buying the dip?

The jam maker's pricing strategy is bolstering its free cash flow.

Elon Musk has big dreams for SpaceX.

One insurer boasts broad international reach and robust cash flow, while the other leans on focused U.S. operations and leaner valuation metrics.

Building retirement savings at 45? These two Canadian stocks could help strengthen your TFSA and RRSP.

These two monthly dividend stocks could help investors build a steadier stream of passive income.

One fund hands you the biggest names in the artificial intelligence build-out for next to nothing in fees. But that convenience comes with a catch.

Làn da có thể trở nên nhạy cảm, khô căng và dễ kích ứng do tác động từ môi trường, treatment hoặc thói quen chăm sóc chưa phù hợp. Đây là lúc kem dưỡng phụ

A TFSA could do serious long-term work when filled with growth and dividend stocks like these.

The BMO Equal Weight Banks Index (TSX:ZEB) stands out as a terrific bet as the Bank of Canada holds off further.

Открытые и публичные торги: как работать с тендерами и не прогореть на первом же контрактеМногие бизнесмены относятся к тендерам как к лотерее: либо повезё

Why this investor sees The Trade Desk as uninvestable until leadership fixes structural growth risks.

These Canadian stocks offer high and sustainable yields and are better positioned to boost the income potential of your portfolio.

How does your TFSA balance stand? How can you improve?

Apple's new Siri AI could be pivotal, but investors must watch real-world adoption and execution.

A $25,000 TFSA could become more productive when invested in dependable dividend stocks.

AktinsRéalis (TSX:ATRL) has a history of severe ethical problems.

North America’s leading cabinetry supplier reported a notable insider buy as shares trade near one-year lows, SEC filings reveal.

This wasn't much of a surprise, given the recent price trajectories of gold and silver.

Discover how to maximize your TFSA through strategic dividend stock investments for tax-free gains and regular income.

Doubling a $7,000 TFSA contribution doesn’t take a lottery ticket, but it does take low fees, diversification, and time for compounding to work.

Green-powered data center operator HIVE reported a notable insider sale amid a year of sharp share price gains and sector volatility.

This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.

Arcutis Biotherapeutics (NASDAQ:ARQT) executives said ZORYVE continues to post strong growth and outlined several regulatory and clinical catalysts expected over the next year, while emphasizing that the company has reached a self-sustaining financial position. Frank, Arcutis’ CEO, said the company